Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Dec 18:15:1499286.
doi: 10.3389/fimmu.2024.1499286. eCollection 2024.

Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification

Jihao Xue #  1 , Qijia Yin #  2   3 , Ming Wang  1 , Yanling Li  4
Affiliations
Comment

Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification

Jihao Xue et al. Front Immunol. .
No abstract available

Keywords: cox regression; glioma; global test; nomogram; proportional hazards (PH) assumption.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Construction and evaluation of the nomogram. (A) Multivariate Cox regression analyses in the TCGA cohort. (B) Nomogram based on age, WHO grade, IDH status, 1p/19q codeletion and PDCL3 expression. (C) Calibration curves showed the concordance between predicted and observed 1-, 3-, and 5-year OS. (D) ROC curve analyses of the nomogram in predicting 1-, 3-, and 5-year OS.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

References

    1. Peng Z, Wang J, Tong S, Wu Y, Yi D, Xiang W. Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification. Front Immunol. (2023) 14:1128151. doi: 10.3389/fimmu.2023.1128151 - DOI - PMC - PubMed
    1. Stensrud MJ, Hernán MA. Why test for proportional hazards? Jama. (2020) 323:1401–2. doi: 10.1001/jama.2020.1267 - DOI - PMC - PubMed
    1. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. (1993) 118:201–10. doi: 10.7326/0003-4819-118-3-199302010-00009 - DOI - PubMed
    1. Fisher LD, Lin DY. Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health. (1999) 20:145–57. doi: 10.1146/annurev.publhealth.20.1.145 - DOI - PubMed
    1. Leon LF, Day BM, Hu XS. If the ratio of hazards R(T)=Λe(T)/Λc(T) does not depend on time T then the proportional hazards assumption holds. J Thorac Oncol. (2013) 8:e116. doi: 10.1097/JTO.0b013e3182a4081f - DOI - PubMed

LinkOut - more resources